Professional Transition Strategies Facilitates 30 Dental Practice Transitions in Q1 2024
The transactions totalled $73 million in enterprise value for dental entrepreneurs
COLORADO SPRINGS, Colo., April 17, 2024 /PRNewswire/ -- Professional Transition Strategies (PTS), a company that facilitates dental practice purchases and mergers & acquisitions, is ecstatic to report it facilitated 30 practice transitions for dental entrepreneurs around the country in Q1 2024.
As the trusted authority in practice transitions, we are pleased to present the following achievements from the past quarter:
30 Successful Transactions: PTS facilitated 30 dental practice transitions, amounting to an enterprise value of $73 million, assisting dentists in achieving their financial goals and ensuring smooth practice handovers
45 New Practices Brought to Market: 45 dental entrepreneurs turned to our team of expert brokers to test the market and begin sourcing competitive offers
$500 Million in Collections: Practices brought to market with us boasted a total collection value of $500 million, underscoring our industry-leading brokerage services that link quality buyers with premium opportunities
147 Prospectuses Created: Our team produced 147 comprehensive prospectuses, equipping both buyers and sellers with the essentials for informed decision-making during the transition process
Over $10.5 million total EBITDA of practices sold: We're thrilled to report an average EBITDA of $620,000 across the practices involved in our deals which totals over $10.5 million
1,700 Practice Inquires: Our proactive marketing strategies led to the generation of 1,700 inquiries, presenting a diverse range of dental practices to prospective DSO and individual buyers
A highlight of the quarter was orchestrating a joint venture deal for a two-location general dentistry practice, with growth opportunities. Initially valued at $7.6 million with a 39% profit margin, we proactively marketed the practice and received interest from 64 qualified parties. In the end, the practice transacted for $28 million to a DSO that offers the doctor-owners future growth options.
"We take huge pride in the exceptional outcomes we deliver for the docs who seek our transition expertise," said Kyle Francis, founder and president of PTS. "We're proud of the strong start to 2024 and look forward to continuing to connect doctor-owners with the unique wealth-building opportunities that are available through the industry's consolidation wave."
As the second quarter begins, PTS is geared up for further growth as the preferred partner for dental professionals seeking a seamless career transition. To learn more about our services or to explore dental practice transition opportunities, please visit professionaltansition.com.
About Professional Transition Strategies Founded in 2006 and headquartered in Colorado Springs, Professional Transition Strategies helps dentists buy, sell or start practices, move to new offices or expand at a current location. The company is committed to client success and provides expert consulting services to help dental professionals improve operations, marketing, accounting and other facets of practice management. Find out more about PTS at www.professionaltransition.com.
Sphere Fluidics, a leading provider of innovative microfluidics-based solutions for single-cell analysis and isolation, today announced the appointment of Dale Levitzke as CEO with immediate effect, as Dr. Frank F. Craig, current CEO and co-founder,...
Scenic Biotech, a pioneer in the field of modifier therapies for severe genetic disorders, today announced that it has entered into a research collaboration with Bristol Myers Squibb to accelerate the development of Bristol Myers Squibb's drug...
As PetSafe® continues to lead the way in pet-tech innovations, we are proud to introduce the next evolution in pet fountains: the PetSafe® Outlasttm 90 oz Pumpless Pet Fountain with patented HydroSpintm technology....
BioMed X, a German biomedical research institute, announces the start of a new research project in partnership with Merck at its site in Heidelberg, Germany. The main objective of the project is to develop novel immunotherapeutic strategies to...
Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announced that the first subject has been dosed in its Phase 1 clinical trial of FP-020 in Australia.
The Phase 1 clinical trial is a randomized, double-blind, placebo-controlled,...
A news report from China Daily:
The 2024 ZGC Forum in Beijing showcased a wide range of latest technological innovations.
The event ran from April 25 to 29 and comprised 128 activities, including forums and conferences, technology exchanges,...